3D Signatures (TSXV:DXD; OTCQB:TDSGF; FSE:3D0) has processed and analyzed the first batch of blood samples for the PRECISE prostate cancer trial at its new laboratory and corporate headquarters in the MaRS Discovery District in Toronto.Read More
Dr. Sabine Mai, a co-founder and principle inventor of 3D Signatures (TSX-V:DXD; OTCQB:TDSGF; FSE:3D0), will present on Feb. 21 at the International Molecular Medicine Tri-Conference in San Francisco, results of a prospective blood-based prostate cancer pilot study using the company’s TeloView software platform.Read More
3D Signatures (TSX-V:DXD) announced its participation in a major clinical trial for prostate cancer diagnosis and management, known as PRECISE, marking the company's first step toward validation and approval of clinical risk assessment tests for prostate cancer.
PRECISE is led by renowned uro-oncologist and prostate cancer thought leader, Dr. Laurence Klotz, who is chairman of the Canadian Urology Research Consortium, the study sponsor.Read More
Senseonics Holdings (NYSE-MKT:SENS) has received CE Mark approval for its Eversense Continuous Glucose Monitoring (CGM) System.
“The CE Mark approval is a significant accomplishment for Senseonics as this application required rigorous regulatory review against high clinical and safety standards,” Dr. Tim Goodnow, CEO and president, said in a statement.Read More